MedWatch

Topotarget CEO: It actually saves us money

Biotech company Topotarget and commercial partner Spectrum Pharmaceuticals have announced a change in the commercialization plans for candidate drug Belinostat. Topotarget’s CEO calls it am ideal agreement.

Foto: PR foto/Topotarget

An altered licensing agreement that now sees Spectrum assuming responsibility for both clinical and commercial production of candidate drug Belinostat for the treatment of peripheral T-cell lymphoma (PTCL) will save Topotarget a great deal of expenses going forward.

“Spectrum already has four marketed products, and Belinostat has to be validated for sale, and that’s a huge process, which Spectrum has gone through several times in the past. For us, in terms of resources, it’s ideal to have Spectrum taking care of that. Furthermore, there are pretty big costs associated with that validation process, which we will now be relieved of,” Topotarget CEO, Anders Vadsholt, tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier